Orphan
AstraZeneca lung drug shows promise
April 20, 2015Sales and Marketing AZ, AZD9291, AstraZeneca, European Lung Cancer Congress, NSCLC, Orphan
AstraZeneca’s non-small cell lung cancer offering AZD9291 has been shown to delay disease progression by over a year. Data presented …
Roche buys French biotech for €470 million
January 19, 2015Sales and Marketing Foundation, Genentech, Orphan, Roche, TRO19622, olesoxime, sma, trophos
Roche is buying France-based biotech Trophos in a deal worth up to €470 million in order to gain access to …
Shortlist announced for best new pharma product
June 24, 2014Research and Development, Sales and Marketing Esbriet, InterMune, Lemtrada, Orphan, dificlir, innovative, pif, prix galion, selincro
Treatments for idiopathic pulmonary fibrosis, hepatic encephalopathy and meningococcal infection are among 14 new medicines shortlisted for the UK Prix …
Biogen gets CHMP thumbs up
May 27, 2014Sales and Marketing Biogen, CHMP, Gazyvaro (obinutuzumab), Nuwiq, Octapharma, Orphan, Roche, chronic lymphocytic leukaemia, plegridy
Biogen Idec is celebrating after the Committee for Medicinal Products for Human Use (CHMP) gave its multiple sclerosis drug Plegridy …
Roche ‘considers’ Alexion bid
July 16, 2013Research and Development, Sales and Marketing Alexion, Orphan, Roche, soliris
Speculation that Roche is considering a bid for rare disease specialist Alexion Pharmaceuticals has unleashed a flurry of comment – …
Orphan drug for Astellas
May 29, 2013Sales and Marketing Astellas, Isavuconazole, Orphan
The FDA has granted orphan designation to one of Astellas’ Phase III drugs designed to treat potentially life-threatening fungal infections …
EU orphan designations rise
February 19, 2013Research and Development, Sales and Marketing COMP, EMA, Orphan, hta
The number of orphan drug designations in the EU is set to rise to record levels this year, according to …
Pfizer forms rare diseases unit
June 15, 2010Research and Development Orphan, Pfizer
Pfizer is seeking to boost its coverage of research into orphan conditions with the creation of a new unit focused …
Orphan and rare disease marketers: are you armed for success?
March 8, 2010Business Services, Sales and Marketing Orphan
Many marketers are currently unfamiliar with the specific approaches required in orphan and rare disease (ORD) brands, but will need …
Single orphan document will simplify process for industry
March 1, 2010Research and Development EMA, FDA, Orphan
The FDA and European Medicines Agency are to simplify the regulatory process for orphan medicines by agreeing to accept a …
GSK looks to rare diseases research
February 5, 2010Research and Development GlaxoSmithKline, Orphan
GlaxoSmithKline has launched a new specialist unit to research and develop medicines for rare diseases. The company has identified 5,500 …
Marketing in rare diseases – getting closer to your customers
January 20, 2010Sales and Marketing Orphan, marketing, marketing ideas, niche
The 21st century healthcare industry is reorientating its strategic focus on the increasingly successful areas of orphan and rare diseases. …
Biopharma company contributes to GSK’s ‘patent pool’
July 10, 2009Research and Development Orphan
Biopharma company Alnylam Pharmaceuticals is to put some of its intellectual property at the disposal of researchers into neglected tropical …
Merck takes aim at neglected tropical diseases
June 25, 2009Research and Development, Sales and Marketing Africa, Merck, Orphan
Merck & Co is participating in two projects designed to help improve healthcare in Africa. The pharma giant will join …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
